Generation of MERRF patient-derived induced pluripotent stem cell line iMERRF-C7

Area of Science:

• Stem cell biology
• Mitochondrial genetics
• Regenerative medicine

Background:

• Mitochondrial disorders, like Myoclonic Epilepsy with Ragged Red Fibers (MERRF), are debilitating genetic conditions.
• Induced pluripotent stem cells (iPSCs) offer a powerful tool for studying disease mechanisms and developing therapies.
• Patient-specific iPSCs can model genetic mutations and cellular phenotypes in vitro.

Purpose of the Study:

• To generate and characterize a human induced pluripotent stem cell (iPSC) line from a patient diagnosed with MERRF.
• To confirm the pluripotency and differentiation capacity of the generated iPSCs.
• To verify the retention of the specific mitochondrial DNA mutation in the iPSC line.

Main Methods:

• Peripheral blood mononuclear cells (PBMCs) were collected from a MERRF patient.
• PBMCs were reprogrammed into iPSCs using Sendai virus-mediated delivery of Yamanaka factors (Oct3/4, Sox2, Klf4, cMyc).
• The generated iPSC line (iMERRF-C7) was assessed for pluripotency markers, differentiation potential, genomic integrity, and the presence of the m.8344 mutation.

Main Results:

• A novel human iPSC line, iMERRF-C7, was successfully established from MERRF patient PBMCs.
• The iPSCs expressed key pluripotency markers and demonstrated the ability to differentiate into derivatives of all three germ layers in vivo.
• The iPSC line maintained the characteristic m.8344 mitochondrial DNA mutation at a similar heteroplasmic level as the patient's cells, with normal genomic structure.
• Non-integrative reprogramming using Sendai virus ensured the genetic stability of the iPSC line.

Conclusions:

• The iMERRF-C7 iPSC line serves as a valuable disease-specific model for studying MERRF.
• This iPSC line retains the pathogenic mitochondrial mutation, enabling research into MERRF pathogenesis and therapeutic strategies.
• The successful generation of this iPSC line highlights the potential of iPSC technology in modeling mitochondrial diseases.